I.W.H. Jarvis
Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues
Jarvis, I.W.H.; Meczes, E.L.; Thomas, H.D.; Edmondson, R.J.; Veal, G.J.; Boddy, A.V.; Ottley, C.J.; Pearson, D.G.; Tilby, M.J.
Authors
E.L. Meczes
H.D. Thomas
R.J. Edmondson
G.J. Veal
A.V. Boddy
Dr Christopher Ottley c.j.ottley@durham.ac.uk
Chief Experimental Officer - Geochemistry
D.G. Pearson
M.J. Tilby
Abstract
Despite an increasing understanding of the molecular mechanisms by which platinum drug DNA adducts interact with cellular processes, the relationship between adduct formation in tumours and clinical response remains unclear. We have determined carboplatin–DNA adduct levels in biopsies removed from ovarian cancer patients following treatment. Reliability of DNA adduct measurements in tissues samples were assessed using experimental animals. Platinum–DNA adduct levels were measured using inductively coupled plasma mass spectrometry (ICP-MS) and plasma drug concentrations determined by atomic absorption spectrometry (AAS). Adduct levels in tissues and plasma pharmacokinetics were determined in Balb/c mice exposed to platinum drugs. Comparisons of adduct levels in tumour and normal tissue were made in nu/nu mice carrying human neuroblastoma xenografts. At 30 min post-cisplatin administration, adduct levels in DNA from kidney and liver were approximately 10- and 6-fold higher than spleen or tumour. By 60 min, levels in liver and kidney, but not spleen or tumour, had fallen considerably. Carboplatin showed high adduct levels only in kidney. Adduct levels in tumour xenografts were comparable to those induced in vitro with similar drug exposures. In clinical samples removed 6 h after drug administration, adduct levels ranged from 1.9 to 4.3 and 0.2 to 3.6 nmol Pt/g DNA for tumour biopsies and peripheral blood mononuclear cells, respectively. No correlation was apparent between these two data sets. The present results demonstrate that reliable measurements of adducts in clinical tumours are feasible. Future results should provide insight into drug resistance.
Citation
Jarvis, I., Meczes, E., Thomas, H., Edmondson, R., Veal, G., Boddy, A., …Tilby, M. (2012). Therapy-induced carboplatin-DNA adduct levels in human ovarian tumours in relation to assessment of adduct measurement in mouse tissues. Biochemical Pharmacology, 83(1), 69-77. https://doi.org/10.1016/j.bcp.2011.10.005
Journal Article Type | Article |
---|---|
Acceptance Date | Oct 4, 2011 |
Online Publication Date | Oct 14, 2011 |
Publication Date | 2012-01 |
Deposit Date | Jan 20, 2012 |
Journal | Biochemical Pharmacology |
Print ISSN | 0006-2952 |
Publisher | Elsevier |
Peer Reviewed | Peer Reviewed |
Volume | 83 |
Issue | 1 |
Pages | 69-77 |
DOI | https://doi.org/10.1016/j.bcp.2011.10.005 |
Public URL | https://durham-repository.worktribe.com/output/1499031 |
You might also like
The effect of magnetic resonance imaging on mercury release from dental amalgam at 3T and 7T
(2022)
Journal Article
Downloadable Citations
About Durham Research Online (DRO)
Administrator e-mail: dro.admin@durham.ac.uk
This application uses the following open-source libraries:
SheetJS Community Edition
Apache License Version 2.0 (http://www.apache.org/licenses/)
PDF.js
Apache License Version 2.0 (http://www.apache.org/licenses/)
Font Awesome
SIL OFL 1.1 (http://scripts.sil.org/OFL)
MIT License (http://opensource.org/licenses/mit-license.html)
CC BY 3.0 ( http://creativecommons.org/licenses/by/3.0/)
Powered by Worktribe © 2025
Advanced Search